Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 30, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 345,000 ordinary shares of 25 pence each.
- Purchase Price: 1,441.82 pence per share.
- Transaction Date: September 30, 2005.
Material Changes
Following the repurchase, the company's share capital structure changed as follows:
- Treasury Shares: The total number of shares held in Treasury increased to 118,133,000.
- Shares in Issue: The number of shares in issue (excluding Treasury shares) stands at 5,828,633,743.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Investor Verification Points
- Verify the total cost of the repurchase by multiplying the 345,000 shares by the 1,441.82 pence price.
- Confirm the updated total share count (5,828,633,743 issued + 118,133,000 treasury) against subsequent filings.
- Note that this filing is a notification of a specific transaction authorized by shareholders on May 25, 2005, rather than a periodic financial report.